A protocol for transdifferentiation of human cardiac fibroblasts into endothelial cells via activation of innate immunity.
A protocol for transdifferentiation of human cardiac fibroblasts into endothelial cells via activation of innate immunity.
复制标题
DOI：
10.1016/j.xpro.2021.100556
复制
发表时间：
2021-06-18
期刊：
影响因子：
--
通讯作者：
Sayed N
中科院分区：
文献类型：
--
作者：
Liu C;Medina P;Thomas D;Chen IY;Sallam K;Sayed D;Sayed N
内皮细胞（EC）由于与心肌细胞接近而成为心脏病的关键致病因素。诱导多能干细胞（iPSC）已被用于产生EC。然而，在临床上，直接将成纤维细胞转分化为EC而不引入多能或病毒驱动的转录因子可能更相关。在这里，我们提出了一个协议，描述了人类心脏成纤维细胞直接转化成内皮细胞，利用先天免疫系统。我们的方案通过第一次传代产生具有95%-98%纯度的真正的人EC。有关本方案使用和执行的完整详细信息，请参见和。一种优化的人内皮细胞（EC）直接重编程方案一种不使用外源性转录因子的临床相关方案该方案利用先天免疫途径进行EC转分化诱导的人EC在第一次传代时可以产生纯度为95%-98%的内皮细胞（EC）由于其与心肌细胞的接近而成为心脏病中的关键致病因素。iPSC已用于产生EC。然而，在临床上，直接将成纤维细胞转分化为EC而不引入多能或病毒驱动的转录因子可能更相关。在这里，我们提出了一个协议，描述了人类心脏成纤维细胞直接转化成内皮细胞，利用先天免疫系统。我们的方案通过第一次传代产生具有95%-98%纯度的真正的人EC。
Endothelial cells (ECs) have emerged as key pathogenic players in cardiac disease due to their proximity with cardiomyocytes. Induced pluripotent stem cells (iPSCs) have been employed to generate ECs. However, it may be more clinically relevant to transdifferentiate fibroblasts into ECs directly without introducing pluripotent or virally driven transcription factors. Here, we present a protocol that describes the direct conversion of human cardiac fibroblasts into ECs by leveraging the innate immune system. Our protocol produces bona fide human ECs with 95%–98% purity by first passage. For complete details on the use and execution of this protocol, please refer to and. An optimized protocol for direct reprogramming of human endothelial cells (ECs) A clinically relevant protocol devoid of the use of exogenous transcription factors The protocol leverages the innate immune pathway for EC transdifferentiation Induced human ECs can be generated with a purity of 95%–98% by first passage Endothelial cells (ECs) have emerged as key pathogenic players in cardiac disease due to their proximity with cardiomyocytes. iPSCs have been employed to generate ECs. However, it may be more clinically relevant to transdifferentiate fibroblasts into ECs directly without introducing pluripotent or virally driven transcription factors. Here, we present a protocol that describes the direct conversion of human cardiac fibroblasts into ECs by leveraging the innate immune system. Our protocol produces bona fide human ECs with 95%–98% purity by first passage.
登录
查看更多内容
影响因子：
23.9
作者：
Zhang, Joe Z.;Termglinchan, Vittavat;Wu, Joseph C.
通讯作者：
Wu, Joseph C.
影响因子：
64.5
作者：
Lee J;Sayed N;Hunter A;Au KF;Wong WH;Mocarski ES;Pera RR;Yakubov E;Cooke JP
通讯作者：
Cooke JP
影响因子：
20.1
作者：
Zhang, Had;Tian, Lei;Wu, Joseph C.
通讯作者：
Wu, Joseph C.
影响因子：
3.7
作者：
Huang X;Shen W;Veizades S;Liang G;Sayed N;Nguyen PK
通讯作者：
Nguyen PK
DOI：
10.1038/nrcardio.2017.57
发表时间：
2017-08
期刊：
Nature reviews. Cardiology
影响因子：
--
作者：
Tallquist MD;Molkentin JD
通讯作者：
Molkentin JD